<?xml version="1.0" encoding="UTF-8"?>
<results title="disease">
 <result pre="10.1007/s11739-020-02389-x : IM-Point of view Potential role of incretins in" exact="diabetes" post="and COVID-19 infection: a hypothesis worth exploring http://orcid.org/0000-0001-8560-6631PantanettiPaolapaola.pantanetti@sanita.marche.it1CangelosiGiovanni1AmbrosioGiuseppe2[1], [2],"/>
 <result pre="the PMC Open Access Subset for unrestricted research re-use and" exact="secondary" post="analysis in any form or by any means with"/>
 <result pre="declaration of COVID-19 as a global pandemic. Abstract Patients with" exact="diabetes mellitus" post="have been reported to be at a high risk"/>
 <result pre="to be at a high risk of complications from SARS-CoV2" exact="virus infection" post="(COVID-19). In type 2 diabetes, there is a change"/>
 <result pre="be at a high risk of complications from SARS-CoV2 virus" exact="infection" post="(COVID-19). In type 2 diabetes, there is a change"/>
 <result pre="high risk of complications from SARS-CoV2 virus infection (COVID-19). In" exact="type 2" post="diabetes, there is a change in immune system cells,"/>
 <result pre="altered immune profile may induce important clinical consequences, including increased" exact="susceptibility to" post="lung infections; and enhanced local inflammatory response. Furthermore, dipeptidyl"/>
 <result pre="Clinical studies should be designed to investigate this possibility. Keywords" exact="Diabetes" post="Dipeptidyl peptidase-4 COVID-19 Gliptins Inflammation Introduction In December 2019,"/>
 <result pre="COVID-19 Gliptins Inflammation Introduction In December 2019, many cases of" exact="viral pneumonia" post="were identified in Wuhan, caused by a new strain"/>
 <result pre="Gliptins Inflammation Introduction In December 2019, many cases of viral" exact="pneumonia" post="were identified in Wuhan, caused by a new strain"/>
 <result pre="virus, coronavirus (SARS-CoV2). In humans, coronaviruses typically cause a mild" exact="disease" post="of the upper respiratory tract, but they can also"/>
 <result pre="In humans, coronaviruses typically cause a mild disease of the" exact="upper" post="respiratory tract, but they can also be associated with"/>
 <result pre="humans, coronaviruses typically cause a mild disease of the upper" exact="respiratory" post="tract, but they can also be associated with more"/>
 <result pre="tract, but they can also be associated with more serious" exact="lung diseases," post="mainly in subjects with multiple comorbidities. In this respect,"/>
 <result pre="mainly in subjects with multiple comorbidities. In this respect, SARS-CoV2" exact="infection" post="may cause a more severe condition, known as COVID-19"/>
 <result pre="curb COVID-19 rapid spread, and minimize its high mortality rate." exact="Diabetes" post="and COVID-19 Epidemiological analyses have found a strong correlation"/>
 <result pre="of pre-existing comorbidities and development of serious diseases following SARS-CoV2" exact="infection" post="[1]. Risk factors associated with development of serious morbidity"/>
 <result pre="gender, advanced age, and number of comorbidities. In particular, diabetes," exact="renal failure," post="cardiac, respiratory, cerebrovascular disease, and hypertension, have all been"/>
 <result pre="number of comorbidities. In particular, diabetes, renal failure, cardiac, respiratory," exact="cerebrovascular disease," post="and hypertension, have all been shown to predispose patients"/>
 <result pre="described during the two previous COV infections, namely the severe" exact="acute" post="respiratory syndrome (SARS) of 2002, which involved more than"/>
 <result pre="during the two previous COV infections, namely the severe acute" exact="respiratory" post="syndrome (SARS) of 2002, which involved more than 8000"/>
 <result pre="the two previous COV infections, namely the severe acute respiratory" exact="syndrome" post="(SARS) of 2002, which involved more than 8000 individuals"/>
 <result pre="8000 individuals mainly in Asia [4], and the Middle East" exact="respiratory" post="syndrome (MERS), which in 2012 affected over 2000 people"/>
 <result pre="individuals mainly in Asia [4], and the Middle East respiratory" exact="syndrome" post="(MERS), which in 2012 affected over 2000 people mainly"/>
 <result pre="in Saudi Arabia [5]. Data on COVID-19 in patients with" exact="diabetes" post="are accumulating. Overall percentage of diabetics affected by COVID-19"/>
 <result pre="major comorbidities of COVID-19 patients who did not survive were" exact="cerebrovascular disease" post="(22%) and diabetes (22%) [6]. A report of 72.314"/>
 <result pre="comorbidities of COVID-19 patients who did not survive were cerebrovascular" exact="disease" post="(22%) and diabetes (22%) [6]. A report of 72.314"/>
 <result pre="patients who did not survive were cerebrovascular disease (22%) and" exact="diabetes" post="(22%) [6]. A report of 72.314 COVID-19 cases by"/>
 <result pre="report of 72.314 COVID-19 cases by the Chinese Center for" exact="Disease" post="Control and Prevention showed an overall mortality of 2.3%,"/>
 <result pre="that a large number of COVID-19 patients are affected by" exact="diabetes" post="(30.5%) [8]. Diabetes and inflammation in the setting of"/>
 <result pre="number of COVID-19 patients are affected by diabetes (30.5%) [8]." exact="Diabetes" post="and inflammation in the setting of COVID-19 Understanding how"/>
 <result pre="Diabetes and inflammation in the setting of COVID-19 Understanding how" exact="diabetes" post="contributes to the severity of the disease, and how"/>
 <result pre="more susceptible to infections, in particular flu and pneumonia. Indeed," exact="diabetes" post="is not just a disorder of glucose metabolism, but"/>
 <result pre="particular flu and pneumonia. Indeed, diabetes is not just a" exact="disorder of glucose metabolism," post="but it can also be viewed as a chronic"/>
 <result pre="glucose metabolism, but it can also be viewed as a" exact="chronic" post="inflammatory state, which is also accompanied by alterations in"/>
 <result pre="lymphocytes impairs immune function, with development of major complications. In" exact="type-2 diabetes," post="there is a change in immune system cells residing"/>
 <result pre="macrophages, and CD1â€‰+â€‰Th1 and Th 17 T cells, interleukin-1 (IL-1)," exact="tumor" post="necrosis factor-Î± (TNF-Î±), which promotes systemic insulin resistance and"/>
 <result pre="T cells, interleukin-1 (IL-1), tumor necrosis factor-Î± (TNF-Î±), which promotes" exact="systemic" post="insulin resistance and pancreatic beta-cell injury (Table 1) [9]."/>
 <result pre="[9]. This altered immune profile induces many consequences, including increased" exact="susceptibility to" post="infections. In patients with viral pneumonia, Guo et al."/>
 <result pre="many consequences, including increased susceptibility to infections. In patients with" exact="viral pneumonia," post="Guo et al. found that the absolute count levels"/>
 <result pre="IL-6 TNF-Î± IL-10 Chemokines IL-11 Interferons IL-13 Dipeptidyl peptidase-4 and" exact="pulmonary" post="inflammation The response to virus-induced tissue damage could result"/>
 <result pre="inflammation The response to virus-induced tissue damage could result in" exact="respiratory" post="failure with acute respiratory distress syndrome (ARDS), characterized by"/>
 <result pre="to virus-induced tissue damage could result in respiratory failure with" exact="acute" post="respiratory distress syndrome (ARDS), characterized by rapid onset of"/>
 <result pre="virus-induced tissue damage could result in respiratory failure with acute" exact="respiratory" post="distress syndrome (ARDS), characterized by rapid onset of widespread"/>
 <result pre="damage could result in respiratory failure with acute respiratory distress" exact="syndrome" post="(ARDS), characterized by rapid onset of widespread inflammation in"/>
 <result pre="are extremely high in subjects with severe/critical COVID-19. Cytokine storm" exact="syndrome" post="(CSS) seems to be of particular concern in patients"/>
 <result pre="IL-6, IL-1, and TNF could be effective for patients in" exact="respiratory" post="insufficiency by COVID-19 [12]. Gut-derived incretins such as glucagon-like"/>
 <result pre="the lungs of healthy subjects, DPP4/CD26 is mainly present on" exact="type I" post="and II alveolar cells, alveolar macrophages, vascular endothelium, and"/>
 <result pre="present on type I and II alveolar cells, alveolar macrophages," exact="vascular" post="endothelium, and pleural mesothelium. Previous studies have shown a"/>
 <result pre="I and II alveolar cells, alveolar macrophages, vascular endothelium, and" exact="pleural" post="mesothelium. Previous studies have shown a direct functional role"/>
 <result pre="studies have shown a direct functional role for DPP4/CD26, in" exact="pulmonary" post="diseases, such as asthma, chronic obstructive pulmonary disease, and"/>
 <result pre="functional role for DPP4/CD26, in pulmonary diseases, such as asthma," exact="chronic" post="obstructive pulmonary disease, and lung fibrosis (Fig.Â 1). Fig."/>
 <result pre="for DPP4/CD26, in pulmonary diseases, such as asthma, chronic obstructive" exact="pulmonary" post="disease, and lung fibrosis (Fig.Â 1). Fig. 1 Mechanistic"/>
 <result pre="pulmonary diseases, such as asthma, chronic obstructive pulmonary disease, and" exact="lung fibrosis" post="(Fig.Â 1). Fig. 1 Mechanistic effects of DPP4 inhibition"/>
 <result pre="from Shao et al. 2020) [13] Dipeptidyl peptidase-4 inhibition and" exact="pulmonary" post="inflammation If DPP4 system is also involved in immunological"/>
 <result pre="used as effective oral hypoglycemic drugs in the treatment of" exact="type-2 diabetes" post="mellitus (T2DM). However, DPP4 inhibition has the potential to"/>
 <result pre="as effective oral hypoglycemic drugs in the treatment of type-2" exact="diabetes mellitus" post="(T2DM). However, DPP4 inhibition has the potential to exert"/>
 <result pre="has the potential to exert a positive pleiotropic effect on" exact="vascular" post="and inflammatory diseases [14, 15], or even direct anti-inflammatory"/>
 <result pre="macrophages, and adipocytes [13, 16, 17]. With specific respect to" exact="lung diseases," post="Kawasaki et al. demonstrated the direct anti-inflammatory effects of"/>
 <result pre="on LPS-induced lung injury in mice and in human lung" exact="epithelial" post="cells. Similarly, DPP4i administration in mice is able to"/>
 <result pre="DPP4 exerted important anti-fibrotic effects in several experimental models of" exact="pulmonary" post="and skin fibrosis [19]. Recently, the DPP4i, Sitagliptin, has"/>
 <result pre="activation in cultured macrophages and in a murine model of" exact="acute" post="lung injury [20]. Given the already established safety profile"/>
 <result pre="might be â€œrepurposedâ€� as potential therapeutic drug candidates for coronavirus" exact="pneumonia" post="in T2DM patients. Interestingly, as gliptins are known to"/>
 <result pre="use of gliptins in modulating the inflammatory response of distal" exact="respiratory" post="tract, with the aim of improving prognosis and reducing"/>
 <result pre="with the aim of improving prognosis and reducing mortality of" exact="respiratory" post="infections in patients with COVID-19. Publisher's Note Springer Nature"/>
 <result pre="the aim of improving prognosis and reducing mortality of respiratory" exact="infections" post="in patients with COVID-19. Publisher's Note Springer Nature remains"/>
 <result pre="Med202010.1007/s11739-020-02355-732385628 2.DengSQPengHJCharacteristics of and public health responses to the coronavirus" exact="disease" post="2019 outbreak in ChinaJ Clin Med202010.3390/jcm902057532093211 3.VioliFPastoriDPignatelliPCangemiRSARS-CoV-2 and myocardial"/>
 <result pre="al.Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected" exact="pneumonia" post="in Wuhan, ChinaJAMA20203231061106910.1001/jama.2020.1585 5.MorraMEVan ThanhLKamelMGet al.Clinical outcomes of current"/>
 <result pre="ThanhLKamelMGet al.Clinical outcomes of current medical approaches for Middle East" exact="respiratory" post="syndrome: a systematic review and meta-analysisRev Med Virol201828e197710.1002/rmv.197729664167 6.YangXYuYXuJet"/>
 <result pre="Respir Med2020847548110.1016/S2213-2600(20)30079-532105632 7.WuZMcGooganJMCharacteristics of and important lessons from the coronavirus" exact="disease" post="2019 (COVID-19) outbreak in China: summary of a report"/>
 <result pre="report of 72 314 cases from the Chinese center for" exact="disease" post="control and preventionJ Am Med Assoc202010.1001/jama.2020.2648 8.Istituto Superiore della"/>
 <result pre="https://www.epicentro.iss.it/en/coronavirus/bollettino/Report-COVID-2019 9.MeshkaniRVakiliSTissue resident macrophages: key players in the pathogenesis of" exact="type 2" post="diabetes and its complicationsClin Chim Acta2016462778910.1016/j.cca.2016.08.01527570063 10.GuoLWeiDZhangXet al.Clinical features"/>
 <result pre="resident macrophages: key players in the pathogenesis of type 2" exact="diabetes" post="and its complicationsClin Chim Acta2016462778910.1016/j.cca.2016.08.01527570063 10.GuoLWeiDZhangXet al.Clinical features predicting"/>
 <result pre="Acta2016462778910.1016/j.cca.2016.08.01527570063 10.GuoLWeiDZhangXet al.Clinical features predicting mortality risk in patients with" exact="viral" post="pneumonia: the MuLBSTA scoreFront Microbiol201910275210.3389/fmicb.2019.0275231849894 11.XuZShiLWangYet al.Pathological findings of"/>
 <result pre="MuLBSTA scoreFront Microbiol201910275210.3389/fmicb.2019.0275231849894 11.XuZShiLWangYet al.Pathological findings of COVID-19 associated with" exact="acute" post="respiratory distress syndromeLancet Respir Med2020842042210.1016/S2213-2600(20)30076-X32085846 12.ShiYWangYShaoCet al.COVID-19 infection: the"/>
 <result pre="scoreFront Microbiol201910275210.3389/fmicb.2019.0275231849894 11.XuZShiLWangYet al.Pathological findings of COVID-19 associated with acute" exact="respiratory" post="distress syndromeLancet Respir Med2020842042210.1016/S2213-2600(20)30076-X32085846 12.ShiYWangYShaoCet al.COVID-19 infection: the perspectives"/>
 <result pre="potential immune modulatory functionsPharmacol Ther202010.1016/j.pharmthera.2020.10750332061923 14.SeferovicPMCoatsAJSPonikowskiPet al.European Society of Cardiology/Heart" exact="Failure" post="Association position paper on the role and safety of"/>
 <result pre="role and safety of new glucose-lowering drugs in patients with" exact="heart" post="failureEur J Heart Fail20202219621310.1002/ejhf.167331816162 15.CattadoriGPantanettiPAmbrosioGGlucose-lowering drugs and heart failure:"/>
 <result pre="of new glucose-lowering drugs in patients with heart failureEur J" exact="Heart" post="Fail20202219621310.1002/ejhf.167331816162 15.CattadoriGPantanettiPAmbrosioGGlucose-lowering drugs and heart failure: implications of recent"/>
 <result pre="in patients with heart failureEur J Heart Fail20202219621310.1002/ejhf.167331816162 15.CattadoriGPantanettiPAmbrosioGGlucose-lowering drugs" exact="and heart" post="failure: implications of recent cardiovascular outcome trials in type"/>
 <result pre="patients with heart failureEur J Heart Fail20202219621310.1002/ejhf.167331816162 15.CattadoriGPantanettiPAmbrosioGGlucose-lowering drugs and" exact="heart" post="failure: implications of recent cardiovascular outcome trials in type"/>
 <result pre="Heart Fail20202219621310.1002/ejhf.167331816162 15.CattadoriGPantanettiPAmbrosioGGlucose-lowering drugs and heart failure: implications of recent" exact="cardiovascular" post="outcome trials in type 2 diabetesDiabetes Res Clin Pract201915710783510.1016/j.diabres.2019.10783531479706"/>
 <result pre="and heart failure: implications of recent cardiovascular outcome trials in" exact="type 2" post="diabetesDiabetes Res Clin Pract201915710783510.1016/j.diabres.2019.10783531479706 16.ReinholdDBankUBÃ¼hlingFKÃ¤hneTKuntDFaustJNeubertKAnsorgeSInhibitors of dipeptidyl peptidase IV"/>
 <result pre="serum levels of TNF-Î±, IL-1Î² and IL-10 in patients with" exact="type 2" post="diabetes mellitusKoomesh2020227177 19.SoareAGyÃ¶rfiHAMateiAEet al.Dipeptidyl-peptidase-4 as a marker of activated"/>
 <result pre="of TNF-Î±, IL-1Î² and IL-10 in patients with type 2" exact="diabetes" post="mellitusKoomesh2020227177 19.SoareAGyÃ¶rfiHAMateiAEet al.Dipeptidyl-peptidase-4 as a marker of activated fibroblasts"/>
 <result pre="and a potential target for the treatment of fibrosis in" exact="Systemic" post="SclerosisArthritis Rheumatol20207213714910.1002/art.4105831350829 20.SadikotRTRubinsteinILong-acting, multi-targeted nanomedicine: addressing unmet medical need"/>
 <result pre="SclerosisArthritis Rheumatol20207213714910.1002/art.4105831350829 20.SadikotRTRubinsteinILong-acting, multi-targeted nanomedicine: addressing unmet medical need in" exact="acute" post="lung injuryJ Biomed Nanotechnol2009561461910.1166/jbn.2009.107820201223"/>
</results>
